sarA inactivation reduces vancomycin-intermediate and ciprofloxacin resistance expression by Staphylococcus aureus

International Journal of Antimicrobial Agents

Volumn 34, Issue 2, 2009, Pages 136-141

  Lamichhane Khadka, Reena ^a   Cantore, Stephanie A ^a   Riordan, James T ^a   Delgado, Alejandro ^a   Norman, Alesha E A ^a   Dueñas, Sarah ^a   Zaman, Shahrear ^a   Horan, Sonia ^b   Wilkinson, Brian J ^c   Gustafson, John E ^a  

^a NEW MEXICO STATE UNIVERSITY   (United States)

^b Las Cruces High School   (United States)

^c ILLINOIS STATE UNIVERSITY   (United States)

Author keywords

Ciprofloxacin; Resistance; sarA; Staphylococcus aureus; VISA

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; MGRA PROTEIN; SIGB PROTEIN; STAPHYLOCOCCAL ACCESSORY REGULATOR A PROTEIN; STAPHYLOCOCCAL ACCESSORY REGULATOR R PROTEIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; AUTOLYSIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE; TRANSCRIPTION REGULATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 67349234879     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.01.018     Document Type: Article

References (55)

1. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med 104 (1998) 7S-10S
2. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
3. Sieradzki K., Roberts R.B., Haber S.W., and Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 340 (1999) 517-523
4. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., Robinson-Dunn B., et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 340 (1999) 493-501
5. Tenover F.C., Biddle J.W., and Lancaster M.V. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 7 (2001) 327-332
6. Tiwari H.K., and Sen M.R. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India. BMC Infect Dis 6 (2006) 156
7. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 51 (2002) 565-567
8. Smith S.M., Eng R.H., and Tecson-Tumang F. Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrob Agents Chemother 33 (1989) 181-184
9. Westblom T.U., Abele B., Blount R., and Hyslop D.L. Successful oral treatment of methicillin-resistant Staphylococcus aureus osteomyelitis using ciprofloxacin. Am J Med 85 (1988) 884
10. Harnett N., Brown S., and Krishnan C. Emergence of quinolone resistance among clinical isolates of methicillin-resistant Staphylococcus aureus in Ontario, Canada. Antimicrob Agents Chemother 35 (1991) 1911-1913
11. O'Brien F.G., Lim T.T., Winnett D.C., Coombs G.W., Pearson J.C., Delgado A., et al. Survey of methicillin-resistant Staphylococcus aureus strains from two hospitals in El Paso, Texas. J Clin Microbiol 43 (2005) 2969-2972
12. Delgado A., Riordan J.T., Lamichhane-Khadka R., Winnett D.C., Jimenez J., Robinson K., et al. Hetero-vancomycin-intermediate methicillin-resistant Staphylococcus aureus isolate from a medical center in Las Cruces, New Mexico. J Clin Microbiol 45 (2007) 1325-1329
13. Perkins H.R., and Nieto M. The chemical basis for the action of the vancomycin group of antibiotics. Ann N Y Acad Sci 235 (1974) 348-363
14. Ferrero L., Cameron B., Manse B., Lagneaux D., Crouzet J., Famechon A., et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 13 (1994) 641-653
15. Ng E.Y., Trucksis M., and Hooper D.C. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother 40 (1996) 1881-1888
16. Cui L., Ma X., Sato K., Okuma K., Tenover F.C., Mamizuka E.M., et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41 (2003) 5-14
17. Mwangi M.M., Wu S.W., Zhou Y., Sieradzki K., de Lencastre H., Richardson P., et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 104 (2007) 9451-9456
18. Pfeltz R.F., and Wilkinson B.J. The escalating challenge of vancomycin resistance in Staphylococcus aureus. Curr Drug Targets Infect Disord 4 (2004) 273-294
19. Sieradzki K., and Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 179 (1997) 2557-2566
20. Pfeltz R.F., Singh V.K., Schmidt J.L., Batten M.A., Baranyk C.S., Nadakavukaren M.J., et al. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Chemother 44 (2000) 294-303
21. Aeschlimann J.R., Kaatz G.W., and Rybak M.J. The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model. J Antimicrob Chemother 44 (1999) 343-349
22. Sakoulas G., Eliopoulos G.M., Moellering Jr. R.C., Wennersten C., Venkataraman L., Novick R.P., et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 46 (2002) 1492-1502
23. O'Leary J.O., Langevin M.J., Price C.T., Blevins J.S., Smeltzer M.S., and Gustafson J.E. Effects of sarA inactivation on the intrinsic multidrug resistance mechanism of Staphylococcus aureus. FEMS Microbiol Lett 237 (2004) 297-302
24. Price C.T., Singh V.K., Jayaswal R.K., Wilkinson B.J., and Gustafson J.E. Pine oil cleaner-resistant Staphylococcus aureus: reduced susceptibility to vancomycin and oxacillin and involvement of SigB. Appl Environ Microbiol 68 (2002) 5417-5421
25. Singh V.K., Schmidt J.L., Jayaswal R.K., and Wilkinson B.J. Impact of sigB mutation on Staphylococcus aureus oxacillin and vancomycin resistance varies with parental background and method of assessment. Int J Antimicrob Agents 21 (2003) 256-261
26. Piriz Duran S., Kayser F.H., and Berger-Bachi B. Impact of sar and agr on methicillin resistance in Staphylococcus aureus. FEMS Microbiol Lett 141 (1996) 255-260
27. Wu S., de Lencastre H., and Tomasz A. Sigma-B, a putative operon encoding alternate sigma factor of Staphylococcus aureus RNA polymerase: molecular cloning and DNA sequencing. J Bacteriol 178 (1996) 6036-6042
28. Truong-Bolduc Q.C., Dunman P.M., Strahilevitz J., Projan S.J., and Hooper D.C. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol 187 (2005) 2395-2405
29. Cheung A.L., and Projan S.J. Cloning and sequencing of sarA of Staphylococcus aureus, a gene required for the expression of agr. J Bacteriol 176 (1994) 4168-4172
30. Riordan J.T., O'Leary J.O., and Gustafson J.E. Contributions of sigB and sarA to distinct multiple antimicrobial resistance mechanisms of Staphylococcus aureus. Int J Antimicrob Agents 28 (2006) 54-61
31. Fujimoto D.F., and Bayles K.W. Opposing roles of the Staphylococcus aureus virulence regulators, Agr and Sar, in Triton X-100- and penicillin-induced autolysis. J Bacteriol 180 (1998) 3724-3726
32. Manna A.C., and Cheung A.L. Expression of SarX, a negative regulator of agr and exoprotein synthesis, is activated by MgrA in Staphylococcus aureus. J Bacteriol 188 (2006) 4288-4299
33. Gustafson J.E., O'Brien F.G., Coombs G.W., Malkowski M.J., Grubb W.B., Pfeltz R.F., et al. Alterations in phage-typing patterns in vancomycin-intermediate Staphylococcus aureus. J Med Microbiol 52 (2003) 711-714
34. Berger-Bachi B. Insertional inactivation of staphylococcal methicillin resistance by Tn551. J Bacteriol 154 (1983) 479-487
35. Kornblum J., Hartman B.J., Novick R.P., and Tomasz A. Conversion of a homogeneously methicillin-resistant strain of Staphylococcus aureus to heterogeneous resistance by Tn551-mediated insertional inactivation. Eur J Clin Microbiol 5 (1986) 714-718
36. Jevons M.P. 'Celbenin'-resistant staphylococci. Br Med J 1 (1961) 124-125
37. Riordan J.T., Muthaiyan A., Van Voorhies W., Price C.T., Graham J.E., Wilkinson B.J., et al. Response of Staphylococcus aureus to salicylate challenge. J Bacteriol 189 (2007) 220-227
38. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 15th informational supplement. Document M100-S15. Wayne, PA: CLSI; 2005.
39. Gustafson J.E., Berger-Bachi B., Strassle A., and Wilkinson B.J. Autolysis of methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob Agents Chemother 36 (1992) 566-572
40. Manna A., and Cheung A.L. Characterization of sarR, a modulator of sar expression in Staphylococcus aureus. Infect Immun 69 (2001) 885-896
41. Luong T.T., Newell S.W., and Lee C.Y. Mgr, a novel global regulator in Staphylococcus aureus. J Bacteriol 185 (2003) 3703-3710
42. Sieradzki K., and Tomasz A. Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell wall synthesis. Microb Drug Resist 4 (1998) 159-168
43. Dunman P.M., Murphy E., Haney S., Palacios D., Tucker-Kellogg G., Wu S., et al. Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci. J Bacteriol 183 (2001) 7341-7353
44. Cassat J., Dunman P.M., Murphy E., Projan S.J., Beenken K.E., Palm K.J., et al. Transcriptional profiling of a Staphylococcus aureus clinical isolate and its isogenic agr and sarA mutants reveals global differences in comparison to the laboratory strain RN6390. Microbiology 152 (2006) 3075-3090
45. Roberts C., Anderson K.L., Murphy E., Projan S.J., Mounts W., Hurlburt B., et al. Characterizing the effect of the Staphylococcus aureus virulence factor regulator, SarA, on log-phase mRNA half-lives. J Bacteriol 188 (2006) 2593-2603
46. McAleese F., Wu S.W., Sieradzki K., Dunman P., Murphy E., Projan S., et al. Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate-S. aureus-type resistance to vancomycin. J Bacteriol 188 (2006) 1120-1133
47. Mongodin E., Finan J., Climo M.W., Rosato A., Gill S., and Archer G.L. Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin. J Bacteriol 185 (2003) 4638-4643
48. Pieper R., Gatlin-Bunai C.L., Mongodin E.F., Parmar P.P., Huang S.T., Clark D.J., et al. Comparative proteomic analysis of Staphylococcus aureus strains with differences in resistance to the cell wall-targeting antibiotic vancomycin. Proteomics 6 (2006) 4246-4258
49. Cirz R.T., Jones M.B., Gingles N.A., Minogue T.D., Jarrahi B., Peterson S.N., et al. Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J Bacteriol 189 (2007) 531-539
50. Chakrabarti S.K., and Misra T.K. SarA represses agr operon expression in a purified in vitro Staphylococcus aureus transcription system. J Bacteriol 182 (2000) 5893-5897
51. Tsuji B.T., Rybak M.J., Lau K.L., and Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 51 (2007) 1089-1091
52. Bischoff M., Dunman P., Kormanec J., Macapagal D., Murphy E., Mounts W., et al. Microarray-based analysis of the Staphylococcus aureus sigmaB regulon. J Bacteriol 186 (2004) 4085-4099
53. Li D., Renzoni A., Estoppey T., Bisognano C., Francois P., Kelley W.L., et al. Induction of fibronectin adhesins in quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin or by sigma B transcription factor activity is mediated by two separate pathways. Antimicrob Agents Chemother 49 (2005) 916-924
54. Truong-Bolduc Q.C., and Hooper D.C. The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and β-lactams in Staphylococcus aureus. J Bacteriol 189 (2007) 2996-3005
55. Truong-Bolduc Q.C., Zhang X., and Hooper D.C. Characterization of NorR protein, a multifunctional regulator of norA expression in Staphylococcus aureus. J Bacteriol 185 (2003) 3127-3138